Earnings Estimates Moving Higher for Pharming Group (PHAR): Time to Buy?Zacks Investment Research • 11/10/25
Does Pharming Group (PHAR) Have the Potential to Rally 100.91% as Wall Street Analysts Expect?Zacks Investment Research • 11/10/25
Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in LondonGlobeNewsWire • 10/30/25
Pharming Group to report third quarter 2025 financial results and provide business update on November 6GlobeNewsWire • 10/23/25
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolioGlobeNewsWire • 10/20/25
Pharming Group provides update on previously announced G&A expense reduction planGlobeNewsWire • 10/06/25
Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 yearsGlobeNewsWire • 10/01/25
Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewsWire • 09/03/25
Wall Street Analysts See a 142.26% Upside in Pharming Group (PHAR): Can the Stock Really Move This High?Zacks Investment Research • 08/22/25
Wall Street Analysts Think Pharming Group (PHAR) Could Surge 145.75%: Read This Before Placing a BetZacks Investment Research • 08/06/25
Pharming Group reports second quarter and first half 2025 financial results and provides business updateGlobeNewsWire • 07/31/25
Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31GlobeNewsWire • 07/17/25
Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosisGlobeNewsWire • 06/24/25
Pharming Group reports on results of the 2025 Annual General Meeting of ShareholdersGlobeNewsWire • 06/11/25
Pharming Group reports first quarter 2025 financial results and provides business updateGlobeNewsWire • 05/08/25